Pretax income is the income that a company earns before paying income taxes. United Therapeutics's pretax income for the
three
months ended in Dec. 2023 was $295 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $1,274 Mil.
United Therapeutics's pretax margin was 48.06%.
During the past 13 years, United Therapeutics's highest Pretax Margin was 71.25%. The lowest was -11.39%. And the median was 45.61%.
United Therapeutics Pre-Tax Income Historical Data
The historical data trend for United Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of United Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, United Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, United Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Pre-Tax Income falls into.
United Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
United Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,274 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (NAS:UTHR) Pre-Tax Income Explanation
United Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, United Therapeutics's highest Pretax Margin was 71.25%. The lowest was -11.39%. And the median was 45.61%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of United Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics (United Therapeutics) Business Description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UTHR has been successfully added to your 